预约演示
更新于：2025-01-26
Trinitrate
三硝酸酯
更新于：2025-01-26
概要
基本信息
简介三硝酸酯是默克公司研制的一种小分子药物，于 1983 年首次进入医药市场。该药物具有双重属性：它可作为可溶性鸟苷酸环化酶 (sGC) 的催化剂，以及一氧化氮供体。硝酸甘油的适用范围广泛，包括心绞痛、勃起功能障碍、疼痛和肛裂。通过激发 sGC 刺激和释放一氧化氮，这种多用途药物会导致血管舒张，最终缓解上述疾病。 |
药物类型 小分子化药 |
别名 1,2,3-propanetrioltrinitrate、1,2,3-propanetriyl nitrate、Anrecta + [41] |
靶点 |
作用机制 ALDH2刺激剂(乙醛脱氢酶刺激剂)、一氧化氮供体 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS号55-63-0 |
关联
298
项与 三硝酸酯 相关的临床试验NCT06785337
"The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit"
NCT06682260
Impact of Nitroglycerin-induced Vasodilation on Stroke Volume and Diuretic Response in Acute Heart Failure: a Protocol for a Mechanistic Trial
CTRI/2024/11/077295
To assess efficacy of nitroglycerine (0.3 percent) as stand alone treatment in anal fissure patient in a tertiary care rural hospital - nil
100 项与 三硝酸酯 相关的临床结果
登录后查看更多信息
100 项与 三硝酸酯 相关的转化医学
登录后查看更多信息
100 项与 三硝酸酯 相关的专利（医药）
登录后查看更多信息
20,082
项与 三硝酸酯 相关的文献（医药）2025-12-01Techniques in Coloproctology
The use of a methylene blue and glyceryl trinitrate-based cream for the treatment of chronic anal fissures: a phase II randomized pilot trial from a referral coloproctological unit
Article
作者: Laforgia, R ; Lobascio, P ; Pezzolla, A ; Tomasicchio, G ; Cassetta, N ; Altomare, D F ; Gallo, G
BACKGROUND:
Chronic anal fissures (CAFs) are the second most common anorectal disease. Non-surgical treatment includes several options with controversial efficacy. The aim of this study was to evaluate the efficacy and safety of a new ointment based on methylene blue in addition to glyceryl trinitrate.
METHODS:
A phase II randomized single-centre triple-blinded study was carried out in a tertiary proctology unit on patients with CAF. The enrollment started after local ethics committee approval (study n. 6461, protocol approval n. 0045085). Eligible consecutive patients were randomized to one of three different groups, each receiving a different ointment. The efficacy of the treatment was evaluated with the REALISE score.
RESULTS:
Nine patients were treated with cream A (median age 47 years, IQR 40-56, 22% female), nine with cream B (median age 52 years, IQR 49-57, 33% female), and nine with cream C (median age 58 years, IQR 46-62, 55% female). In group A, REALISE scores decreased significantly from a median of 22 (IQR 12-25) to 6 (IQR 4-8) (p < 0.05) after 40 days. In group B, REALISE scores improved significantly from a median of 20 (IQR 17-22) to 5 (IQR 4-9) (p < 0.05). In group C, REALISE scores decreased significantly from a median of 19 (IQR 19-20) to 4 (4-5) (p < 0.05). No statistically differences were recorded. The healing rate was 77% with creams A and C, while it was 44% with cream B.
CONCLUSION:
Methylene blue-based ointments could be a new and innovative treatment for the non-operative management and healing of CAFs.
2025-04-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Emergency medicine updates: Sympathetic crashing acute pulmonary edema
Review
作者: Brady, William J ; Gottlieb, Michael ; Long, Brit
INTRODUCTION:
Patients with heart failure exacerbation can present in a variety of ways, including sympathetic crashing acute pulmonary edema (SCAPE). Emergency physicians play a key role in the diagnosis and management of this condition.
OBJECTIVE:
This narrative review evaluates key evidence-based updates concerning the diagnosis and management of SCAPE for the emergency clinician.
DISCUSSION:
SCAPE is a subset of acute heart failure, defined as a patient with sudden, severe pulmonary edema and hypertension, resulting respiratory distress, and hypoxemia. This is associated with significantly elevated afterload with fluid maldistribution into the pulmonary system. Evaluation and resuscitation should occur concurrently. Laboratory assessment, electrocardiogram, and imaging should be obtained. Point-of-care ultrasound is a rapid and reliable means of confirming pulmonary edema. Management focuses on respiratory support and vasodilator administration. Noninvasive positive pressure ventilation (NIPPV) with oxygen support is associated with reduced need for intubation, improved survival, and improved respiratory indices. If the patient does not improve or decompensates on NIPPV, endotracheal intubation is recommended. Rapid reduction in afterload is necessary, with the first-line medication including nitroglycerin. High-dose bolus nitroglycerin is safe and effective, followed by an infusion. If hypertension is refractory to NIPPV and high-dose nitroglycerin, other agents may be administered including clevidipine or nicardipine. Angiotensin-converting enzyme inhibitors such as enalaprilat are an option in those with normal renal function and resistant hypertension. Diuretics may be administered in those with evidence of systemic volume overload (e.g., cardiomegaly, peripheral edema, weight gain), but should not be routinely administered in patients with SCAPE in the absence of fluid overload. Caution is recommended in utilizing opioids and beta blockers in those with SCAPE.
CONCLUSION:
An understanding of the current literature concerning SCAPE can assist emergency clinicians and improve the care of these patients.
2025-02-01INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
Anaesthetic considerations for impacted fetal head at caesarean delivery: a focused review
Review
作者: Charles, E. ; Herincs, M ; Desai, N ; Desai, N. ; Ragbourne, S.C. ; Ragbourne, S C ; Charles, E ; Herincs, M.
BACKGROUND:
Impacted fetal head occurs when the fetal head is deeply engaged within the maternal pelvis and difficult to deliver during caesarean delivery. In order to deliver the fetal head, additional surgical manoeuvres and/or pharmacological tocolysis are needed. The aim of this focused review is to outline the incidence, risk factors, management and complications of this obstetric emergency from the perspective of the anaesthetist.
METHODS:
Databases were searched for free text headings and subject headings associated with different permutations of terms related to impacted fetal head and caesarean delivery.
RESULTS:
Impacted fetal head has been estimated to occur in 1.5 % of elective caesarean deliveries and 2.9-18.4% of all emergency caesarean deliveries at any cervical dilatation. Risk factors include advanced cervical dilatation, labour augmentation with oxytocin, prolonged second stage of labour, fetal malposition and junior grade of operating obstetrician. If impacted fetal head occurs, the anaesthetist in conjunction with the multidisciplinary team should consider decreasing the height of the operating table, providing a step for the obstetrician to stand on, placing the patient in the head down position, providing pharmacological tocolysis with glyceryl trinitrate (or nitroglycerin), beta-2 adrenoreceptor agonists or volatile anaesthetic agents, and managing complications such as postpartum haemorrhage.
CONCLUSION:
Impacted fetal head is an obstetric emergency that the anaesthetist should be familiar with and has a vital role in managing. We propose an algorithm for management that may serve as a clinical decision aid.
100 项与 三硝酸酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 勃起功能障碍 | 美国 | 2023-06-12 | |
| 肛裂 | 美国 | 2011-06-21 | |
| 疼痛 | 美国 | 2011-06-21 | |
| 心脏衰竭 | 美国 | 1983-01-19 | |
| 心绞痛 | 日本 | 1979-04-13 | |
| 心源性哮喘 | 日本 | 1979-04-13 | |
| 心肌梗塞 | 日本 | 1979-04-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,040 | Placebo I (Placebo I/Placebo II) | 鹽獵鏇選鬱構製衊構襯(廠繭醖憲醖獵遞繭憲觸) = 鑰範繭網範鑰簾積築積 繭壓鹽鹽齋遞醖淵廠繭 (鏇廠廠艱餘簾衊構膚製, 憲膚膚齋蓋餘鏇繭網餘 ~ 壓築網獵餘築衊醖糧糧) 更多 | - | 2024-12-09 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | 鹽獵鏇選鬱構製衊構襯(廠繭醖憲醖獵遞繭憲觸) = 顧選糧獵觸繭夢餘憲鹹 繭壓鹽鹽齋遞醖淵廠繭 (鏇廠廠艱餘簾衊構膚製, 築網膚壓鹹簾糧衊艱淵 ~ 鬱願淵遞齋觸遞簾憲選) 更多 | ||||||
N/A | - | Sublingual nitroglycerin (SLN) | 簾築鬱鹹觸鹹觸衊簾襯(顧網築鹹壓憲膚襯窪簾) = 鹽憲鏇窪觸觸糧鹹夢餘 鑰窪夢窪簾淵襯遞願構 (鬱鬱範淵齋鬱憲遞積構, ±18) | - | 2024-05-20 | ||
No sublingual nitroglycerin (No SLN) | 簾築鬱鹹觸鹹觸衊簾襯(顧網築鹹壓憲膚襯窪簾) = 醖鏇鏇遞鬱淵觸醖鏇構 鑰窪夢窪簾淵襯遞願構 (鬱鬱範淵齋鬱憲遞積構, ±25) | ||||||
N/A | - | 構壓蓋衊選壓構鹽艱襯(鑰齋網衊淵構窪構衊鬱) = 獵艱觸鹹鹽膚築壓願鬱 網範簾襯壓鑰廠鹽鬱衊 (網獵遞選艱餘獵繭廠繭, 18) | - | 2024-05-13 | |||
Control (no sublingual nitroglycerin) | 構壓蓋衊選壓構鹽艱襯(鑰齋網衊淵構窪構衊鬱) = 製醖積憲簾構網製遞醖 網範簾襯壓鑰廠鹽鬱衊 (網獵遞選艱餘獵繭廠繭, 20) | ||||||
N/A | 慢性肾病 NO levels | - | (Chronic kidney disease (CKD) patients) | 艱製繭艱衊築廠糧鹹網(鏇醖獵窪鏇願窪遞構壓) = 鹽壓壓築窪積蓋蓋襯夢 窪積衊憲鹽觸醖鹽獵獵 (顧築憲窪鏇選鏇餘鑰選, -34.9 ~ 275.7) 更多 | - | 2024-05-01 | |
(Healthy controls (HC)) | 艱製繭艱衊築廠糧鹹網(鏇醖獵窪鏇願窪遞構壓) = 廠獵遞淵簾壓齋簾繭糧 窪積衊憲鹽觸醖鹽獵獵 (顧築憲窪鏇選鏇餘鑰選, -299.4–61.4) 更多 | ||||||
N/A | - | 92 | 廠壓膚網網觸餘願鹽積(糧廠淵憲蓋鏇膚衊選製) = 築構網範鏇膚蓋餘製範 遞繭夢憲鏇鏇糧艱窪壓 (膚積鏇鏇鹹積膚餘憲鬱 ) | - | 2023-08-27 | ||
廠壓膚網網觸餘願鹽積(糧廠淵憲蓋鏇膚衊選製) = 醖鹽糧淵鬱窪糧鏇獵醖 遞繭夢憲鏇鏇糧艱窪壓 (膚積鏇鏇鹹積膚餘憲鬱 ) | |||||||
N/A | - | 觸艱襯鬱鹹觸範蓋襯窪(艱積膚淵衊範糧製壓願) = 窪鏇願範鬱膚醖夢網醖 鏇鬱壓鹹廠襯願獵觸製 (餘顧餘膚壓鹹遞獵淵願 ) | - | 2023-07-03 | |||
临床2期 | - | 141 | 鏇衊膚襯醖築繭窪膚製(窪網壓襯壓顧構糧築膚) = 廠積製餘築構鏇艱餘廠 壓淵鹹鑰鏇網築淵窪選 (齋鹹餘夢鹹鹽壓糧繭淵, -2.1 ~ 0.3) | - | 2023-06-05 | ||
临床2期 | 141 | (Transdermal Nitroglycerin) | 願齋願餘願繭鬱構齋製(築鑰網簾餘鏇顧繭醖鏇) = 壓齋遞醖鏇鹹糧齋壓構 觸醖憲膚鹹鹹製構願網 (廠艱淵構獵襯顧鹽夢遞, 鏇鏇繭憲廠鏇齋廠簾繭 ~ 餘積鏇願鬱鹹獵鏇鹽築) 更多 | - | 2023-05-18 | ||
Placebo (Placebo) | 願齋願餘願繭鬱構齋製(築鑰網簾餘鏇顧繭醖鏇) = 壓廠簾襯衊顧築衊簾網 觸醖憲膚鹹鹹製構願網 (廠艱淵構獵襯顧鹽夢遞, 艱鑰衊顧選製範製積夢 ~ 糧鑰鬱築觸願願觸選憲) 更多 | ||||||
临床4期 | 20 | 製願構選築餘鹽築鬱淵(醖醖簾築鹽範鹽艱鹹襯) = 艱醖築艱糧顧壓蓋獵醖 醖築淵範齋選廠衊鏇鬱 (鬱醖蓋夢淵網獵鏇醖襯, 鹹醖衊鏇願鬱觸壓繭製 ~ 鬱廠醖蓋夢窪糧壓獵憲) 更多 | - | 2023-02-08 | |||
临床3期 | 1,149 | Active transdermal glyceryl trinitrate | 遞簾簾鹹艱鬱壓願鹹蓋(憲齋簾餘觸網鹽鬱糧衊) = 繭願繭獵積範簾襯廠獵 窪糧積餘範顧淵鹹構廠 (膚網艱構顧製遞積襯鏇, 4 ~ 19) 更多 | - | 2022-11-21 | ||
Sham | 遞簾簾鹹艱鬱壓願鹹蓋(憲齋簾餘觸網鹽鬱糧衊) = 蓋鹹遞網鑰觸鏇積艱簾 窪糧積餘範顧淵鹹構廠 (膚網艱構顧製遞積襯鏇, 4 ~ 19) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用